Free Trial
NASDAQ:OPGN

OpGen (OPGN) Stock Price, News & Analysis

OpGen logo
$4.15 +0.03 (+0.73%)
As of 03:46 PM Eastern

About OpGen Stock (NASDAQ:OPGN)

Key Stats

Today's Range
$3.94
$4.27
50-Day Range
$0.69
$4.15
52-Week Range
$0.53
$8.40
Volume
9,512 shs
Average Volume
7,435 shs
Market Capitalization
$34.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Remove Ads
Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Stock News Headlines

StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)
OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
OpGen Appoints New COO and Company Secretary
OPGN Stock Earnings: OpGen Reported Results for Q2 2024
See More Headlines

OPGN Stock Analysis - Frequently Asked Questions

OpGen's stock was trading at $0.5950 at the beginning of 2025. Since then, OPGN stock has increased by 597.5% and is now trading at $4.15.
View the best growth stocks for 2025 here
.

OpGen, Inc. (NASDAQ:OPGN) posted its earnings results on Thursday, August, 10th. The medical research company reported ($9.30) EPS for the quarter, missing analysts' consensus estimates of ($7.10) by $2.20. The medical research company earned $0.74 million during the quarter, compared to analysts' expectations of $0.90 million.

OpGen shares reverse split before market open on Monday, May 20th 2024. The 1-10 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

OpGen (OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OpGen investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Broadcom (AVGO).

Company Calendar

Last Earnings
8/10/2023
Today
4/02/2025
Next Earnings (Estimated)
6/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:OPGN
Employees
100
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,670,000.00
Net Margins
-1,140.36%
Pretax Margin
-742.42%

Debt

Sales & Book Value

Annual Sales
$2.67 million
Price / Cash Flow
N/A
Book Value
($11.55) per share
Price / Book
-0.36

Miscellaneous

Free Float
4,696,000
Market Cap
$34.68 million
Optionable
Not Optionable
Beta
0.34

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:OPGN) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners